• Publications
  • Influence
Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the
TLDR
Despite toxicity, MRD reduction by alemtuzumab consolidation translates into a significantly improved long‐term clinical outcome.
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
TLDR
This analysis supports the hypothesis that for the evaluated regimens, a correlation exists between capecitabine-attributed ST and treatment efficacy regarding DCR, PFS, and OS.
Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma
TLDR
Re-RT/BEV→BEV is safe, feasible and effective and deserves further prospective evaluation.
Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer
TLDR
Severe leukopenia seems avoidable in weekly scheduled single-agent docetaxel and may serve as an important treatment option, particularly in elderly patients and patients with a reduced performance status.
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
TLDR
Her2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms†
TLDR
The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B‐cell neoplasm as administered by office‐based haematologists in Germany, and 91% of first‐line treatments were successful (40% complete response).
High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer
TLDR
The weekly administration of docetaxel is highly efficient and safe as first-line treatment for MBC and may serve as an important treatment option specifically in elderly patients and patients with a reduced performance status.
Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL
TLDR
The CLL1 protocol, a randomized phase III trial of the GCLLSG, was conducted to assess if the early use of fludarabine prolongs progression free survival (PFS) in high risk (HR) CLL pts, but not the OS in this group of patients.
Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms
TLDR
Dose‐dense two‐weekly ‘R‐CHOP‐14’ was not superior over three‐weekly’ in randomised clinical trials (RCTs) and real‐world data on effectiveness of R‐CHop‐14 and R‐ CHOP‐21 in patients with DLBCL treated in German routine practice is presented.
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized
TLDR
It is demonstrated that the addition of cetuximab to CAPIRI or CAPOX is effective and safe in first-line treatment of mCRC and a trend toward longer survival was associated with KRAS wild-type.
...
1
2
3
4
5
...